Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos, et al.
Clinical Lymphoma Myeloma & Leukemia (2018) Vol. 18, Iss. 10, pp. e401-e419
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
Rafaël Fonseca, Saad Z. Usmani, Maneesha Mehra, et al.
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 80
Anti CD38 monoclonal antibodies for multiple myeloma treatment
Alessandro Gozzetti, Sara Ciofini, Martina Simoncelli, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 51
Drug repurposing for cancer therapy, easier said than done
Aurora González‐Fierro, Alfonso Dueñas‐González
Seminars in Cancer Biology (2019) Vol. 68, pp. 123-131
Closed Access | Times Cited: 56
Multiple myeloma: Role of autologous transplantation
Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Efstathios Kastritis, et al.
Cancer Treatment Reviews (2019) Vol. 82, pp. 101929-101929
Closed Access | Times Cited: 55
Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Mohamad Ali Hijazi, André Gessner, Nahed El‐Najjar
Cancers (2023) Vol. 15, Iss. 12, pp. 3199-3199
Open Access | Times Cited: 16
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Evangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, et al.
Annals of Hematology (2020) Vol. 99, Iss. 5, pp. 1049-1061
Closed Access | Times Cited: 37
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Luca Bertamini, Giuseppe Bertuglia, Stefania Oliva
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 19
Novel Treatment Options for Multiple Myeloma
Andrew J. Portuguese, Rahul Banerjee, Gui Zhen Chen, et al.
JCO Oncology Practice (2025)
Closed Access
Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study
Kihyun Kım, Estelle Verburgh, Т. А. Митина, et al.
International Journal of Hematology (2025)
Closed Access
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
Arthur Bobin, Évelyne Liuu, Niels Moya, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2885-2885
Open Access | Times Cited: 29
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐CD38 Antibodies: The EMMY Cohort From 2017 to 2020
Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
Caitlin Costello, Faith E. Davies, Gordon Cook, et al.
Future Oncology (2019) Vol. 15, Iss. 13, pp. 1411-1428
Open Access | Times Cited: 28
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
Jill Corre, Aurore Perrot, Cyrille Hulin, et al.
Leukemia (2021) Vol. 35, Iss. 12, pp. 3600-3603
Closed Access | Times Cited: 21
Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance
Vincenzo Sammartano, Alfonso Cerase, Valentina Venanzi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
Hedwig M. Blommestein, Chrissy H.Y. van Beurden-Tan, M Franken, et al.
Haematologica (2019) Vol. 104, Iss. 5, pp. 1026-1035
Open Access | Times Cited: 24
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
Sikander Ailawadhi, Sundar Jagannath, Hans C. Lee, et al.
Cancer (2020) Vol. 126, Iss. 19, pp. 4332-4340
Open Access | Times Cited: 23
Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?
Aurora González‐Fierro, Adriana Romo‐Pérez, Alma Chávez‐Blanco, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 227-239
Open Access | Times Cited: 7
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Nieves Lopez-Munoz, Gema Hernández, Rafael Alonso, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 7
Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
Alessandro Gozzetti, Donatella Raspadori, Francesca Bacchiarri, et al.
Journal of Personalized Medicine (2020) Vol. 10, Iss. 3, pp. 120-120
Open Access | Times Cited: 17
Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
Fatih M. Uckun, Sanjive Qazi, Taner Demirer, et al.
EBioMedicine (2018) Vol. 39, pp. 612-620
Open Access | Times Cited: 17
Real-World Treatment of Patients With Relapsed/Refractory Myeloma
Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Evangelos Terpos, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 6, pp. 379-385
Closed Access | Times Cited: 13
Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study
Sujith Dhanasiri, G. Hollier-Hann, CA Stothard, et al.
Clinical Therapeutics (2021) Vol. 43, Iss. 11, pp. 1983-1996.e3
Open Access | Times Cited: 13
Drug resistance and minimal residual disease in multiple myeloma
Alessandro Gozzetti, Sara Ciofini, Anna Sicuranza, et al.
Cancer Drug Resistance (2022)
Open Access | Times Cited: 9
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
Agoston Gyula Szabo, Katrine Fladeland Iversen, Sören Möller, et al.
Clinical Hematology International (2019)
Open Access | Times Cited: 14
Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom
Mohamad Mohty, Wolfgang Knauf, Dorothy Romanus, et al.
European Journal Of Haematology (2020) Vol. 105, Iss. 3, pp. 308-325
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top